{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T19:35:25Z","timestamp":1768073725892,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,17]]},"DOI":"10.7759\/cureus.90354","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:58:27Z","timestamp":1755500307000},"source":"Crossref","is-referenced-by-count":1,"title":["A Phase-II Investigator-Initiated Randomized, Double-Blind, Parallel-Group Clinical Trial of 5-Aminolevulinic Acid Hydrochloride\/Sodium Ferrous Citrate (5-ALA-HCl\/SFC) for Patients With Adult-Onset Still\u2019s Disease (AOSD) Refractory to Corticosteroids"],"prefix":"10.7759","author":[{"given":"Remi","family":"Sumiyoshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Kamisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimpei","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamiki","family":"Hikake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyoshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.974881","article-title":"Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan","volume":"25","author":"Asanuma YF","year":"2015","unstructured":"Asanuma YF, Mimura T, Tsuboi H, Noma H, Miyoshi F, Yamamoto K, Sumida T. Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan. Mod Rheumatol. 2015, 25:393-400. 10.3109\/14397595.2014.974881","journal-title":"Mod Rheumatol"},{"key":"ref2","article-title":"Adult Still's disease: A multicenter survey of Japanese patients","volume":"17","author":"Ohta A","year":"1990","unstructured":"Ohta A, Yamaguchi M, Tsunematsu T, et al.. Adult Still's disease: A multicenter survey of Japanese patients. J Rheumatol. 1990, 17:1058-63.","journal-title":"J Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225854","article-title":"Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): A systematic review informing the EULAR\/PReS guidelines for the management of Still's disease","volume":"83","author":"Bindoli S","year":"2024","unstructured":"Bindoli S, De Matteis A, Mitrovic S, Fautrel B, Carmona L, De Benedetti F. Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): A systematic review informing the EULAR\/PReS guidelines for the management of Still's disease. Ann Rheum Dis. 2024, 83:1731-47. 10.1136\/ard-2024-225854","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2014.02.003","article-title":"5-Aminolevulinic acid combined with ferrous iron enhances the expression of heme oxygenase-1","volume":"19","author":"Nishio Y","year":"2014","unstructured":"Nishio Y, Fujino M, Zhao M, et al.. 5-Aminolevulinic acid combined with ferrous iron enhances the expression of heme oxygenase-1. Int Immunopharmacol. 2014, 19:300-7. 10.1016\/j.intimp.2014.02.003","journal-title":"Int Immunopharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/ar1721","article-title":"Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: Use in the differential diagnosis of hyperferritinemia","volume":"7","author":"Kirino Y","year":"2005","unstructured":"Kirino Y, Takeno M, Iwasaki M, et al.. Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: Use in the differential diagnosis of hyperferritinemia. Arthritis Res Ther. 2005, 7:R616-24. 10.1186\/ar1721","journal-title":"Arthritis Res Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.27.1.4862","article-title":"Heme oxygenase-1: The \"emerging molecule\" has arrived","volume":"27","author":"Morse D","year":"2002","unstructured":"Morse D, Choi AM. Heme oxygenase-1: The \"emerging molecule\" has arrived. Am J Respir Cell Mol Biol. 2002, 27:8-16. 10.1165\/ajrcmb.27.1.4862","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.11.034","article-title":"5-Aminolevulinic acid regulates the inflammatory response and alloimmune reaction","volume":"37","author":"Fujino M","year":"2016","unstructured":"Fujino M, Nishio Y, Ito H, Tanaka T, Li XK. 5-Aminolevulinic acid regulates the inflammatory response and alloimmune reaction. Int Immunopharmacol. 2016, 37:71-8. 10.1016\/j.intimp.2015.11.034","journal-title":"Int Immunopharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00275.2013","article-title":"5-Aminolevulinic acid combined with ferrous iron induces carbon monoxide generation in mouse kidneys and protects from renal ischemia-reperfusion injury","volume":"305","author":"Hou J","year":"2013","unstructured":"Hou J, Cai S, Kitajima Y, et al.. 5-Aminolevulinic acid combined with ferrous iron induces carbon monoxide generation in mouse kidneys and protects from renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2013, 305:F1149-57. 10.1152\/ajprenal.00275.2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080850","article-title":"5-Aminolevulinic acid protects against cisplatin-induced nephrotoxicity without compromising the anticancer efficiency of cisplatin in rats in vitro and in vivo","volume":"8","author":"Terada Y","year":"2013","unstructured":"Terada Y, Inoue K, Matsumoto T, et al.. 5-Aminolevulinic acid protects against cisplatin-induced nephrotoxicity without compromising the anticancer efficiency of cisplatin in rats in vitro and in vivo. PLoS One. 2013, 8:e80850. 10.1371\/journal.pone.0080850","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2014.09.037","article-title":"5-Aminolevulinic acid with ferrous iron induces permanent cardiac allograft acceptance in mice via induction of regulatory cells","volume":"34","author":"Hou J","year":"2015","unstructured":"Hou J, Zhang Q, Fujino M, et al.. 5-Aminolevulinic acid with ferrous iron induces permanent cardiac allograft acceptance in mice via induction of regulatory cells. J Heart Lung Transplant. 2015, 34:254-63. 10.1016\/j.healun.2014.09.037","journal-title":"J Heart Lung Transplant"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1422231","article-title":"Beneficial use of serum ferritin and heme oxygenase-1 as biomarkers in adult-onset Still's disease: A multicenter retrospective study","volume":"28","author":"Kirino Y","year":"2018","unstructured":"Kirino Y, Kawaguchi Y, Tada Y, et al.. Beneficial use of serum ferritin and heme oxygenase-1 as biomarkers in adult-onset Still's disease: A multicenter retrospective study. Mod Rheumatol. 2018, 28:858-64. 10.1080\/14397595.2017.1422231","journal-title":"Mod Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013, 310:2191-4. 10.1001\/jama.2013.281053","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.12048","article-title":"Combination of 5-aminolevulinic acid and ferrous ion reduces plasma glucose and hemoglobin A1c levels in Zucker diabetic fatty rats","volume":"6","author":"Hara T","year":"2016","unstructured":"Hara T, Koda A, Nozawa N, et al.. Combination of 5-aminolevulinic acid and ferrous ion reduces plasma glucose and hemoglobin A1c levels in Zucker diabetic fatty rats. FEBS Open Bio. 2016, 6:515-28. 10.1002\/2211-5463.12048","journal-title":"FEBS Open Bio"},{"key":"ref14","article-title":"Preliminary criteria for classification of adult Still's disease","volume":"19","author":"Yamaguchi M","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, et al.. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992, 19:424-30.","journal-title":"J Rheumatol"},{"key":"ref15","article-title":"Clinical Practice Guideline for Adult Still's","author":"Sumida TM","year":"2017","unstructured":"Sumida TM, T. Iwamoto, M. Ota, A. Ota, A. Okamoto, N. Okiyama, N. Clinical Practice Guideline for Adult Still's. Disease. 2017,","journal-title":"Disease"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto N","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, et al.. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012, 367:2396-406. 10.1056\/NEJMoa1205099","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/art.30238","article-title":"Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis","volume":"63","author":"Vojinovic J","year":"2011","unstructured":"Vojinovic J, Damjanov N, D'Urzo C, et al.. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011, 63:1452-8. 10.1002\/art.30238","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: A randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko Y","year":"2018","unstructured":"Kaneko Y, Kameda H, Ikeda K, et al.. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: A randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018, 77:1720-9. 10.1136\/annrheumdis-2018-213920","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109846","article-title":"Efficacy and safety of 5-aminolevulinic acid in adult-onset Still's disease: A preclinical study in mice and a pilot study in humans","volume":"257","author":"Koga T","year":"2023","unstructured":"Koga T, Sumiyoshi R, Tsuji Y, Kodama K, Endo Y, Furukawa K, Kawakami A. Efficacy and safety of 5-aminolevulinic acid in adult-onset Still's disease: A preclinical study in mice and a pilot study in humans. Clin Immunol. 2023, 257:109846. 10.1016\/j.clim.2023.109846","journal-title":"Clin Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022708","article-title":"Single-arm, open-label pilot intervention study to investigate an effect of oral 5-aminolevulinic acid plus sodium ferrous citrate on glucocorticoid reduction in patients with adult-onset Still disease: Study protocol for clinical trial (SPIRIT compliant)","volume":"99","author":"Sumiyoshi R","year":"2020","unstructured":"Sumiyoshi R, Koga T, Shimizu T, et al.. Single-arm, open-label pilot intervention study to investigate an effect of oral 5-aminolevulinic acid plus sodium ferrous citrate on glucocorticoid reduction in patients with adult-onset Still disease: Study protocol for clinical trial (SPIRIT compliant). Medicine (Baltimore). 2020, 99:e22708. 10.1097\/MD.0000000000022708","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/398702-a-phase-ii-investigator-initiated-randomized-double-blind-parallel-group-clinical-trial-of-5-aminolevulinic-acid-hydrochloridesodium-ferrous-citrate-5-ala-hclsfc-for-patients-with-adult-onset-stills-disease-aosd-refractory-to-corticosteroids","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:58:27Z","timestamp":1755500307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/398702-a-phase-ii-investigator-initiated-randomized-double-blind-parallel-group-clinical-trial-of-5-aminolevulinic-acid-hydrochloridesodium-ferrous-citrate-5-ala-hclsfc-for-patients-with-adult-onset-stills-disease-aosd-refractory-to-corticosteroids"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,17]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.90354","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,17]]}}}